GlassScriptPhysician profile
Amol Saxena
NPI 1851402242
$109,694.13
in general payments reported to CMS, 2019-2025
9 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Sports Medicine (Podiatrist) providers received nationally (typical 2025 total: $307).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,197 · 2020: $13K · 2021: $33K · 2022: $6,593 · 2023: $25K · 2024: $2,754 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Travel and Lodging: $16K · Royalty Or License: $4,273 · Honoraria: $3,500 · Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,006.39 |
| Travel and Lodging | $16,242.45 |
| Royalty Or License | $4,272.54 |
| Honoraria | $3,500.00 |
| Food and Beverage | $1,097.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Extremity Medical | $44,770.79 | 2019-2025 | Io Fix |
| Medical Device Business Services, INC. | $31,065.00 | 2020-2021 | |
| Trimed, INC. | $21,751.61 | 2019-2025 | |
| Teleflex Medical Incorporated | $8,426.15 | 2019-2024 | Weck, Deknatel |
| Arthrex, INC. | $2,503.28 | 2019-2021 | |
| Voom Medical Devices, INC. | $846.94 | 2024 | Revcon |
| Stryker Corporation | $170.13 | 2024 | Invision, Prophecy, Inbone |
| Linvatec Corporation | $128.18 | 2025 | Neospan, Ibs, Biobrace 23mm |
| Amniox Medical, INC. | $32.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amol Saxena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.